Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Researchers from Novartis, Department of Immunology describe findings in vaccines
September 10th, 2008
New investigation results, 'Alum adjuvanticity: unraveling a century old mystery,' are detailed in a study published in European Journal of Immunology. According to recent research from Siena, Italy, "The development of vaccine adjuvants for human use has been one of the slowest processes in the history of medicine. For almost one century, aluminium hydroxide (alum) has been the only vaccine adjuvant approved worldwide." "Only in the past decade have two oil-in-water emulsions and one TLR agonist been approved by the European authorities as new vaccine adjuvants. Despite the fact that alum has been injected into billions of people, its mechanism of action is not...
Source: Vaccine Weekly (2008-09-10)
|
